NVO vs. TEM: Novo Nordisk vs. Tempus AI Stock Comparison

Company Profile

Novo Nordisk (NVO) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVO is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

Novo Nordisk (NVO) carries decades of public-market history since April 30, 1981, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the NVO side.

Tempus AI (TEM) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Novo Nordisk (NVO) is defensive at 0.67 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novo Nordisk (NVO) reports 58.38%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Novo Nordisk (NVO) reports 33.92%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Novo Nordisk (NVO) reports 40.05%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Novo Nordisk (NVO) at 6.43% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Novo Nordisk (NVO) reports EPS growth of 1.77%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Novo Nordisk (NVO) at 0.62 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novo Nordisk (NVO) trades at 10.18 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Novo Nordisk (NVO) at 5.43 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics